Efficacy of deferasirox in patients with thalassaemia major is not affected by a history of hepatitis B OR C
Saved in:
Main Authors: | Cappellini, M.D., Elalfy, M., El-Beshlawy, A., Kattamis, A., Chan, L.L., Li, C., Lin, K.H., Quarta, G., Sutcharitchan, P., Taher, A., Habr, D., Roubert, B., Porter, J. |
---|---|
Format: | Article |
Published: |
2010
|
Subjects: | |
Online Access: | http://eprints.um.edu.my/13338/ |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Deferasirox effectively removes cardiac iron in beta-thalassaemia patients with myocardial siderosis previously chelated with deferoxamine monotherapy or deferoxamine-deferiprone therapy
by: Pennell, D., et al.
Published: (2010) -
Continued improvement in cardiac T2*with deferasirox treatment over 2 years: Results from the extension of epic cardiac substudy in beta-thalassaemia patients with myocardial siderosis
by: Pennell, D., et al.
Published: (2010) -
Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia
by: Pennell, D.J., et al.
Published: (2010) -
Continued improvement and normalization of myocardial T2*in patients with beta-thalassemia major treated with deferasirox (Exjade (R)) for up to 3 years
by: Pennell, D., et al.
Published: (2010) -
Tailoring iron chelation by iron intake and serum ferritin: The prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias
by: Cappellini, M.D., et al.
Published: (2010)